Objective Lupus nephritis (LN) is a prevalent renal manifestation in patients with SLE, with kidney biopsy remaining the gold ...

Purpose Renal flares contribute substantially to morbidity, renal survival and death in systemic lupus erythematosus (SLE). Identification of pharmacological strategies for the prevention of renal ...

Objectives To identify antiphospholipid antibody-associated thrombocytopenia (aPLs-TP) phenotypes and assess their clinical outcomes. Methods This single-centre, prospective cohort study (January 2012 ...

Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

Objective To assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory cutaneous lupus erythematosus (CLE) and lupus non-specific ...

Pregnancy increases the risk of flare in patients with SLE and is associated with excess fetal morbidity and mortality.1 The management of pregnant patients with lupus is difficult, partly because ...

Objectives Neuropsychiatric SLE (NPSLE) lacks evidence-based treatment strategies. This study compared the effectiveness and safety profiles of obinutuzumab (OBZ) and rituximab (RTX) in patients with ...

An estimated 50% of patients with SLE will develop lupus nephritis in their lifetime, with people of African descent more likely to have adverse kidney outcomes and reduced response to therapy.1 2 ...

Background Systemic lupus erythematosus (SLE) is uncommon after the age of 50. The aim of this study was to determine clinical, biological and immunological characteristics of late-onset SLE. Patients ...

Objective To determine whether subclinical brain dysfunction in SLE can be detected by disrupted interhemispheric connectivity and assess its modulation by immunosuppressive regimens. Methods 234 ...